Applied DNA Reports Fiscal Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Applied DNA Sciences (APDN) Misses Q3 EPS by 5c
August 6, 2020 5:28 PM EDTApplied DNA Sciences (NASDAQ: APDN) reported Q3 EPS of ($0.72), $0.05 worse than the analyst estimate of ($0.67).
We continued during the quarter to position the Company to serve the unmet and evolving needs for COVID-19 testing solutions and vaccine development, said Dr. James A. Hayward, president and CEO of Applied DNA Sciences. Upon the receipt of FDA Emergency Use Authorization (EUA) for our Linea COVID-19 diagnostic assay kit (for use with nasopharyngeal (NP) swab and anterior nasal swab (ANS) sample collections), we put into place the foundation of our COVID-19 diagnostics business: we established the requisite supply... More
